Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor

NCT02601274 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
33
Enrollment
INDUSTRY
Sponsor class

Stopped the change of clinical development plan

Conditions

Interventions

Sponsor

Hutchison Medipharma Limited